{"Clinical Trial ID": "NCT00232479", "Intervention": ["INTERVENTION 1:", "Group 1", "Patients received a dense dose of herceptin, carboplatin, and taxotere."], "Eligibility": ["Incorporation criteria:", "HER-2 overexpressing breast cancer", "Clinical stage 2-3B", "Normal ejection fraction", "- Exclusion criteria:", "Metastatic diseases", "Low ejection fraction"], "Results": ["Performance measures:", "Number of patients with a complete pathological response (CPR)", "PCR is defined as the absence of invasive tumours of the breast surgical sample and the axilla obtained after chemotherapy has been administered.", "Time limit: determined at the time of surgery, i.e. approximately 16 weeks from the start of treatment.", "Results 1:", "Title of arm/group: Group 1", "Description of the arm/group: patients received a dense dose of herceptin, carboplatin, and taxotere", "Total number of participants analysed: 44", "Type of measurement: Number", "Unit of measurement: participants 19"], "Adverse Events": ["Undesirable Events 1:", "Total: 1/46 (2.17 per cent)", "Hospitality [1]1/46 (2.17 %)"]}